IL1B and neoplasm: Although a significant improvement in weight loss or DAI score was not observed (Supplementary Figures S2B, C), treatment with the tmTNF-α antibody significantly inhibited the production of proinflammatory mediators, including IL-1β, IL-6, and NO, but prompted the release of the anti-inflammatory cytokine IL-10 in colonic tissue homogenates at both the inflammation and tumor stages (Figures 6A–D).